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• Pseudomonas aeruginosa (Pa) is a leading cause of lung infection 
in patients with cystic fibrosis (CF), increasing morbidity and 
mortality
• Inadequate and/or improper treatment of Pa infections can lead to 
chronic colonization, making eradication more unlikely
• Despite numerous clinical trials, there is still no standardized 
treatment among the medical community for Pa eradication in 
patients with CF
• The Nebraska Regional Cystic Fibrosis Center at Children’s 
Hospital and Medical Center (CHMC) in Omaha, Nebraska has 
their own Pa eradication protocol
Methods
• Retrospective medical chart review of 1–21 year-olds with CF at 
CHMC
• Patients without enough documentation in their medical record to 
extrapolate date were excluded
• Medical records were screened for Pa culture results and 
subsequent treatments. Patient’s treatments not aligning with the 
treatment protocol were considered getting “non-protocol 
treatment”
• Primary endpoints measured included: degree of Pa protocol 
adherence and eradication success and chronic colonization 
following set protocol vs non-protocol treatments
• Current protocol (Figure 1) starts on Step 1 with inhaled 
tobramycin x28 days and ciprofloxacin x14 days
• If sustained positivity, the patient is started on Step 2 with10-
14 days of intravenous antibiotics
• If still positive after this point, they progress to Step 3 with 6 
months of alternating monthly inhaled tobramycin, colistin, or 
aztreonam
• Patient is considered colonized if they are Pa positive following 
Step 3
• After a negative sputum culture following a step, Pa is considered 
eradicated, they continue quarterly monitoring, and they restart 
the protocol following another positive Pa result
Figure 1. Pseudomonas aeruginosa Eradication 
Protocol
Results
• 172 of the 184 patients on CHMC’s CF registry were included in the 
study (8 excluded for age and 4 for inadequate medical records)
• Protocol was followed correctly for 70.3% of all patients
• This study aims to increase Pa eradication for children with CF by 
investigating the effectiveness and adherence to the current Pa
eradication protocol used at CHMC
• It is hypothesized that close adherence to the current Pa eradication 
protocol will be associated with higher levels of eradication at each 
step and patients will have lower levels of chronic colonization
Figure 2. Pseudomonas aeruginosa Colonization 
Following Protocol vs Non-protocol Treatment.
• As shown in figure 2, when the protocol was fully followed, 12/121 
(9.9%) of patients become colonized with Pa compared to 27/51 
(52.9%) of patients who did not follow the protocol (odds ratio 
0.099, 95% CI 0.04-0.22, P-value= <0.0001)
Conclusion
• Adherence to the current Pa eradication protocol was associated 
with increased Pa eradication levels when used at step one. 
However, there was no statistical significance when comparing 
protocol steps two and three to non-protocol treatment
• Patients fully adhering to the protocol had fewer cases of Pa
colonization. However, 70.3% of patients fully followed the 
protocol
• Limitations of this study: retrospective nature, inability to follow 
treatment compliance, health status when screened for Pa, 
confounding co-morbidities
• Further work is needed to compare CHMC’s Pa eradication 
protocol to others to help create a globally standardized protocol. 
Recurrent evaluation of CHMC’s current protocol will have to 
proceed as advances in CF treatment continue (i.e. Trikafta)
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Odds ratio (95% 
CI) P-value
Step 1 
eradication 151 (73.3%) 36 (59.0%) 0.52 (0.29-0.95) 0.03
Step 2 
eradication 22 (37.9%) 11 (45.8%) 1.38 (0.53-3.62) 0.51
Step 3 
eradication 10 (23.3%) 3 (75%) 9.9 (0.92-106.03) 0.06
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